This site is intended only for healthcare professionals resident in the Republic of Ireland

Search

Menu

Close

Sign in or RegisterLog out
Our medicinesTherapy areasExplore contentExplore contentMaterialsVideosPodcastsLet’s connectLet's connectContact usSign up

Menu

Close

AboutInfliximabWhat is infliximabMechanism of actionBiosimilarsApprovalOverviewPosition statementsECCOEULARESPGHANDosing & SwitchingDosingIV dosingAdministration & storageIV administrationStorageSafety informationImportant safety informationSwitchingConsiderations for switchingSafety informationImportant safety informationSafety informationImportant safety informationClinical EvidenceRandomised controlled trial evidenceSummary: randomised controlled trial evidenceSupport & ResourcesMaterials
Position statements: EULAR

The European Alliance of Associations for Rheumatology (EULAR) is a European medical association focused on arthritis/rheumatism1

The EULAR PARE (people with arthritis/rheumatism across Europe) Representation Committee gathers representatives of rheumatic and musculoskeletal user groups around Europe to work together towards improving the quality of life for people in Europe living with these conditions2

EULAR (PARE) released an updated position paper in 2018 that supports the use of biosimilars in appropriate patients with rheumatic diseases3

“If so-called ‘naïve’ patients (patients who have not taken a biologic so far) should take a biologic, the less expensive biologic (either originator or biosimilar) can be used – as long as there are no contraindications, the patient has been informed and the decision is based on a shared decision between rheumatologist and patient”3“Overall, studies suggest that the one-time switch of therapy from the respective original product to its biosimilar has no effect on efficacy and safety3

Please refer to the INFLECTRA® Summary of Product Characteristics for full prescribing information

References:EULAR web site. About EULAR. Available at: https://www.eular.org/whoweare Accessed May 2023.EULAR web site. EULAR PARE Representation Committee. Available at: https://www.eular.org/the-eular-pare-community Accessed May 2023.EULAR. Position Paper on Biosimilars. August 2018.
Position statements
Considerations for switching

Learn about considerations when switching to INFLECTRA®

Explore Loading

Legal Category: S1A
Further information is available upon request

PP-IFA-IRL-0146 May 2023

Adverse events should be reported. Report an adverse event to your national reporting system (HPRA Pharmacovigilance)
 

Adverse events should also be reported to Pfizer Medical Information on 1800 633 363

PfizerPro AccountPfizerPro Account

Please sign in or register to gain access to information relating to Pfizer medicines and vaccines, medical conditions, patient materials and services.

Sign in or RegisterRegisterAccountLog out

This site is intended only for healthcare professionals resident in the Republic of Ireland. If you are a member of the public wishing to access information on a specific medicine, please visit https://www.medicines.ie

 

This website is brought to you by Pfizer Healthcare Ireland, 9 Riverwalk, National Digital Park, Citywest Business Campus, Dublin 24, Ireland. Registered in the Republic of Ireland No. 127002.

 

Copyright © 2023 Pfizer Limited. All rights reserved.

PP-UNP-IRL-0176. January 2023
For Healthcare Professionals in the Republic of Ireland *

The information contained on this site is reserved exclusively for healthcare professionals resident in the Republic of Ireland.

I confirm that I am a healthcare professional resident in the Republic of Ireland.*

I accept and agree to the terms of use.*

If you select 'No', you will be redirected to Pfizer.ie, where you will be able to access information on Pfizer Healthcare Ireland.

PP-UNP-IRL-0176. January 2023

Yes No
You are now leaving PfizerPro
You are now leaving PfizerPro Ireland. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer. Pfizer accepts no responsibility for the content or services of the linked site.